LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Behavioral intervention to reduce opioid overdose among high-risk persons with opioid use disorder: A pilot randomized controlled trial.

    Coffin, Phillip Oliver / Santos, Glenn-Milo / Matheson, Tim / Behar, Emily / Rowe, Chris / Rubin, Talia / Silvis, Janelle / Vittinghoff, Eric

    PloS one

    2017  Volume 12, Issue 10, Page(s) e0183354

    Abstract: Objective: The United States is amidst an opioid epidemic, including synthetic opioids that may result in rapid death, leaving minimal opportunity for bystander rescue. We pilot tested a behavioral intervention to reduce the occurrence of opioid ... ...

    Abstract Objective: The United States is amidst an opioid epidemic, including synthetic opioids that may result in rapid death, leaving minimal opportunity for bystander rescue. We pilot tested a behavioral intervention to reduce the occurrence of opioid overdose among opioid dependent persons at high-risk for subsequent overdose.
    Materials and methods: We conducted a single-blinded randomized-controlled trial of a repeated dose motivational interviewing intervention (REBOOT) to reduce overdose versus treatment as usual, defined as information and referrals, over 16 months at the San Francisco Department of Public Health from 2014-2016. Participants were 18-65 years of age, had opioid use disorder by Structured Clinical Interview, active opioid use, opioid overdose within 5 years, and prior receipt of naloxone kits. The intervention was administered at months 0, 4, 8, and 12, preceded by the assessment which was also administered at month 16. Dual primary outcomes were any overdose event and number of events, collected by computer-assisted personal interview, as well as any fatal overdose events per vital records.
    Results: A total of 78 persons were screened and 63 enrolled. Mean age was 43 years, 67% were born male, 65% White, 17% African-American, and 14% Latino. Ninety-two percent of visits and 93% of counseling sessions were completed. At baseline, 33.3% of participants had experienced an overdose in the past four months, with a similar mean number of overdoses in both arms (p = 0.95); 29% overdosed during follow-up. By intention-to-treat, participants assigned to REBOOT were less likely to experience any overdose (incidence rate ratio [IRR] 0.62 [95%CI 0.41-0.92, p = 0.019) and experienced fewer overdose events (IRR 0.46, 95%CI 0.24-0.90, p = 0.023), findings that were robust to sensitivity analyses. There were no differences between arms in days of opioid use, substance use treatment, or naloxone carriage.
    Conclusions: REBOOT reduced the occurrence of any opioid overdose and the number of overdoses.
    Trial registration: clinicaltrials.gov NCT02093559.
    MeSH term(s) Adolescent ; Adult ; Aged ; Drug Overdose/prevention & control ; Female ; Humans ; Male ; Middle Aged ; Narcotic Antagonists/administration & dosage ; Opioid-Related Disorders/prevention & control ; Pilot Projects ; Risk Factors ; Single-Blind Method ; Treatment Outcome ; Young Adult
    Chemical Substances Narcotic Antagonists
    Language English
    Publishing date 2017
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial
    ISSN 1932-6203
    ISSN (online) 1932-6203
    DOI 10.1371/journal.pone.0183354
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Behavioral intervention to reduce opioid overdose among high-risk persons with opioid use disorder

    Phillip Oliver Coffin / Glenn-Milo Santos / Tim Matheson / Emily Behar / Chris Rowe / Talia Rubin / Janelle Silvis / Eric Vittinghoff

    PLoS ONE, Vol 12, Iss 10, p e

    A pilot randomized controlled trial.

    2017  Volume 0183354

    Abstract: The United States is amidst an opioid epidemic, including synthetic opioids that may result in rapid death, leaving minimal opportunity for bystander rescue. We pilot tested a behavioral intervention to reduce the occurrence of opioid overdose among ... ...

    Abstract The United States is amidst an opioid epidemic, including synthetic opioids that may result in rapid death, leaving minimal opportunity for bystander rescue. We pilot tested a behavioral intervention to reduce the occurrence of opioid overdose among opioid dependent persons at high-risk for subsequent overdose.We conducted a single-blinded randomized-controlled trial of a repeated dose motivational interviewing intervention (REBOOT) to reduce overdose versus treatment as usual, defined as information and referrals, over 16 months at the San Francisco Department of Public Health from 2014-2016. Participants were 18-65 years of age, had opioid use disorder by Structured Clinical Interview, active opioid use, opioid overdose within 5 years, and prior receipt of naloxone kits. The intervention was administered at months 0, 4, 8, and 12, preceded by the assessment which was also administered at month 16. Dual primary outcomes were any overdose event and number of events, collected by computer-assisted personal interview, as well as any fatal overdose events per vital records.A total of 78 persons were screened and 63 enrolled. Mean age was 43 years, 67% were born male, 65% White, 17% African-American, and 14% Latino. Ninety-two percent of visits and 93% of counseling sessions were completed. At baseline, 33.3% of participants had experienced an overdose in the past four months, with a similar mean number of overdoses in both arms (p = 0.95); 29% overdosed during follow-up. By intention-to-treat, participants assigned to REBOOT were less likely to experience any overdose (incidence rate ratio [IRR] 0.62 [95%CI 0.41-0.92, p = 0.019) and experienced fewer overdose events (IRR 0.46, 95%CI 0.24-0.90, p = 0.023), findings that were robust to sensitivity analyses. There were no differences between arms in days of opioid use, substance use treatment, or naloxone carriage.REBOOT reduced the occurrence of any opioid overdose and the number of overdoses.clinicaltrials.gov NCT02093559.
    Keywords Medicine ; R ; Science ; Q
    Subject code 150
    Language English
    Publisher Public Library of Science (PLoS)
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial.

    Coffin, Phillip Oliver / Santos, Glenn-Milo / Das, Moupali / Santos, Deirdre M / Huffaker, Shannon / Matheson, Tim / Gasper, James / Vittinghoff, Eric / Colfax, Grant N

    Addiction (Abingdon, England)

    2013  Volume 108, Issue 4, Page(s) 751–761

    Abstract: Aims: To test aripiprazole for efficacy in decreasing use in methamphetamine-dependent adults, compared to placebo.: Design: Participants were randomized to receive 12 weeks of aripiprazole or placebo, with a 3-month follow-up and a platform of ... ...

    Abstract Aims: To test aripiprazole for efficacy in decreasing use in methamphetamine-dependent adults, compared to placebo.
    Design: Participants were randomized to receive 12 weeks of aripiprazole or placebo, with a 3-month follow-up and a platform of weekly 30-minute substance abuse counseling.
    Setting: The trial was conducted from January 2009 to March 2012 at the San Francisco Department of Public Health.
    Participants: Ninety actively using, methamphetamine-dependent, sexually active adults were recruited from community venues.
    Measurements: The primary outcome was regression estimated reductions in weekly methamphetamine-positive urines. Secondary outcomes were study medication adherence [by self-report and medication event monitoring systems (MEMS)], sexual risk behavior and abstinence from methamphetamine.
    Findings: Participant mean age was 38.7 years, 87.8% were male, 50.0% white, 18.9% African American, and 16.7% Latino. Eighty-three per cent of follow-up visits and final visits were completed. By intent-to-treat, participants assigned to aripiprazole had similar reductions in methamphetamine-positive urines as participants assigned to placebo [risk ratio (RR) 0.88, 95% confidence interval (CI): 0.66-1.19, P = 0.41]. Urine positivity declined from 73% (33 of 45 participants) to 45% (18 of 40) in the placebo arm and from 77% (34 of 44) to 44% (20 of 35) in the aripiprazole arm. Adherence by MEMS and self-report was 42 and 74%, respectively, with no significant difference between arms (MEMS P = 0.31; self-report P = 0.17). Most sexual risk behaviors declined similarly among participants in both arms (all P > 0.05). There were no serious adverse events related to study drug, although participants randomized to aripiprazole reported more akathisia, fatigue and drowsiness (P < 0.05).
    Conclusion: Compared with placebo, aripiprazole did not reduce methamphetamine use significantly among actively using, dependent adults.
    MeSH term(s) Adult ; Amphetamine-Related Disorders/rehabilitation ; Amphetamine-Related Disorders/urine ; Aripiprazole ; Combined Modality Therapy ; Counseling ; Dopamine Agonists/therapeutic use ; Double-Blind Method ; Female ; Humans ; Male ; Medication Adherence ; Methamphetamine ; Piperazines/therapeutic use ; Quinolones/therapeutic use ; Substance Abuse Detection ; Treatment Failure
    Chemical Substances Dopamine Agonists ; Piperazines ; Quinolones ; Methamphetamine (44RAL3456C) ; Aripiprazole (82VFR53I78)
    Language English
    Publishing date 2013-01-03
    Publishing country England
    Document type Comparative Study ; Journal Article ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural
    ZDB-ID 1141051-6
    ISSN 1360-0443 ; 0965-2140
    ISSN (online) 1360-0443
    ISSN 0965-2140
    DOI 10.1111/add.12073
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top